Clinical trial
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and…
NCT00256698 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00256698 |
|---|---|
| Title | Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy |
| Official title | FACT: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy; an Open Randomized, Comparative, Phase III Multicentre Study in Postmenopausal Women With Hormone Receptor Positive Breast Cancer in First Relapse After Primary Treatment of… |
| Acronym | FACT |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Fulvestrant, Anastrozole |
| Enrollment | 514 |
| Start date | Jan 1, 2004 |
| Primary completion | Apr 1, 2009 |
| Completion | Feb 1, 2012 |
| First posted | Nov 22, 2005 |
| Last update posted | Aug 1, 2012 |
| Countries | Canada, Costa Rica, Finland, France, Germany, Guatemala, Iceland, Italy, Norway, Portugal, Sweden, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: